NYSE ARCA | ETF
The fund employs a passive management - or indexing - investment approach designed to track the performance of the underlying index.
It will normally invest at least 80% of its net assets in securities that comprise the underlying index.
The underlying index is comprised of small and mid-cap stocks of biotechnology companies that have one or more drugs in either Phase II or Phase III of theU. S.
Food and Drug Administration clinical trials.
Top 20 Holdings
| Asset | Name | Sector | Industry | Weight |
|---|---|---|---|---|
| CERE | Cerevel Therapeutics Holdings Inc | Healthcare | Biotechnology | 4.18% |
| PCVX | Vaxcyte Inc | Healthcare | Biotechnology | 4.06% |
| ALKS | Alkermes Plc | Healthcare | Drug Manufacturers - Specialty & Generic | 3.27% |
| ACAD | ACADIA Pharmaceuticals Inc | Healthcare | Biotechnology | 3.26% |
| RVMD | Revolution Medicines Inc | Healthcare | Biotechnology | 3.07% |
| AXSM | Axsome Therapeutics Inc | Healthcare | Biotechnology | 2.78% |
| IMCR | Immunocore Holdings Ltd | Healthcare | Biotechnology | 2.42% |
| XENE | Xenon Pharmaceuticals Inc | Healthcare | Biotechnology | 2.34% |
| MLTX_old | Multex Com Inc | Other | Other | 2.26% |
| SMMT | Summit Therapeutics PLC | Healthcare | Biotechnology | 1.86% |
| CBAY | Cymabay Therapeu | Healthcare | Biotechnology | 1.84% |
| DNLI | Denali Therapeutics Inc | Healthcare | Biotechnology | 1.81% |
| CORT | Corcept Therapeutics Incorporated | Healthcare | Biotechnology | 1.80% |
| GLPG | Galapagos NV ADR | Healthcare | Biotechnology | 1.79% |
| ACLX | Arcellx Inc | Healthcare | Biotechnology | 1.79% |
| IDYA | Ideaya Biosciences Inc | Healthcare | Biotechnology | 1.73% |
| CRNX | Crinetics Pharmaceuticals Inc | Healthcare | Biotechnology | 1.73% |
| SWTX | SpringWorks Therapeutics Inc | Healthcare | Biotechnology | 1.69% |
| NTLA | Intellia Therapeutics Inc | Healthcare | Biotechnology | 1.68% |
| RYTM | Rhythm Pharmaceuticals Inc | Healthcare | Biotechnology | 1.64% |